Abstract
The TGFβ type I receptor kinase (ALK5) is an attractive target for intervention in TGFβ signaling due to its druggability as well as its centrality and specificity in the pathway. A number of potent, selective ALK5 inhibitors have been discovered which interact with the ATP-binding site of ALK5. Crystallographic studies of these molecules bound to ALK5 have provided an understanding of potency and selectivity achieved by these inhibitors. ALK5 kinase inhibitors are potently active in models of cancer due to mechanisms of action similar to those for other TGFβ inhibitory agents. Recent insights into the function of TGFβ in human tumors as well as in preclinical models of cancer are helping to identify potential target patient populations and drug combinations for the development of ALK5 kinase inhibitors and other TGFβ- targeted therapeutics. Differences in the toxicological effects, pharmacokinetics and clinical side effects of ALK5 kinase inhibitors and other TGFβ-targeted agents provide a useful and differentiated set of TGFβ signaling inhibitory agents to investigate in clinical studies.
Keywords: Transforming growth factor-β, Cancer, Transforming growth factor-β type I receptor kinase inhibitor, Activin receptor-like kinase 5 inhibitor, ALK5 inhibitor, Transforming growth factor-β receptor kinase inhibitor, human tumors, Smad-mediated gene expression, clinical trials, targeted therapies, ALK5 small molecule binding pockets, Smad signaling, kinase inhibitors, hydrophobic back pocket, hydrogen bond
Current Pharmaceutical Biotechnology
Title: TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Volume: 12 Issue: 12
Author(s): Leona E. Ling and Wen-Cherng Lee
Affiliation:
Keywords: Transforming growth factor-β, Cancer, Transforming growth factor-β type I receptor kinase inhibitor, Activin receptor-like kinase 5 inhibitor, ALK5 inhibitor, Transforming growth factor-β receptor kinase inhibitor, human tumors, Smad-mediated gene expression, clinical trials, targeted therapies, ALK5 small molecule binding pockets, Smad signaling, kinase inhibitors, hydrophobic back pocket, hydrogen bond
Abstract: The TGFβ type I receptor kinase (ALK5) is an attractive target for intervention in TGFβ signaling due to its druggability as well as its centrality and specificity in the pathway. A number of potent, selective ALK5 inhibitors have been discovered which interact with the ATP-binding site of ALK5. Crystallographic studies of these molecules bound to ALK5 have provided an understanding of potency and selectivity achieved by these inhibitors. ALK5 kinase inhibitors are potently active in models of cancer due to mechanisms of action similar to those for other TGFβ inhibitory agents. Recent insights into the function of TGFβ in human tumors as well as in preclinical models of cancer are helping to identify potential target patient populations and drug combinations for the development of ALK5 kinase inhibitors and other TGFβ- targeted therapeutics. Differences in the toxicological effects, pharmacokinetics and clinical side effects of ALK5 kinase inhibitors and other TGFβ-targeted agents provide a useful and differentiated set of TGFβ signaling inhibitory agents to investigate in clinical studies.
Export Options
About this article
Cite this article as:
E. Ling Leona and Lee Wen-Cherng, TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808257
DOI https://dx.doi.org/10.2174/138920111798808257 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Herbal Based Polymeric Nanoparticles as a Therapeutic Remedy for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry